Recurrent's $700 million claim on Moonshot cites a 10.5% stake that $30 billion would value at $3.15 billion

Cryptopolitan's account gives two descriptions of the demand that do not fit together. One puts it at roughly $700 million ^[1]. The other says Recurrent and its investors seek compensation equal to 10.5% of Moonshot's shares, worth more than $700 million at the $30 billion valuation of the June funding ^[4]. Ten and a half percent of $30 billion is $3.15 billion ^[12], 4.5 times the headline figure ^[17]. Run the other way, $700 million is 2.3% of $30 billion ^[13], and a 10.5% stake is worth that much only on a base of about $6.7 billion ^[16], a little over a fifth of the June valuation. Even the one-point gap between the 9.5% Recurrent first acquired and the 10.5% it now seeks ^[3] comes to $300 million at $30 billion ^[15]. The account does not say which base Recurrent used.

We'd treat $700 million as the working figure, since the account uses it as the demand, and the percentage as unexplained. That leaves two readings of the 10.5%: it was applied to an older, lower valuation, or it was misreported. The third reading is that $700 million is a floor under a claim near $3.15 billion. A tribunal document or a prospectus that shows the 10.5% applied to the $30 billion valuation would put the exposure at $3.15 billion and make our reading wrong.

The allegations are the disclosure problem. The letter says Zhang Yutao received a substantial stake in Moonshot and did not disclose it to Recurrent's shareholders ^[24]. It also says he instructed the deletion of other critical information in September 2024 ^[23]. These are allegations in a claimant's letter, and the claimant's board includes the two men it accuses: Yang Zhilin and Zhang are both directors of Recurrent ^[7].

Moonshot filed initial paperwork confidentially in September ^[20]. Cryptopolitan judged that the dispute is unlikely to derail the listing entirely ^[10], while one source said an unresolved case could raise flags on compliance, corporate governance and ownership transparency and complicate regulatory vetting ^[8]. We'd expect Moonshot to want the amount and its base agreed on paper before it files publicly, because a risk factor that cannot state its own exposure invites the questions that source describes.